Fmoc-Pro(Cl) | 103321-52-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-Pro(Cl)
• 英文别名: (9H-fluoren-9-yl)methyl 2-(chlorocarbonyl)pyrrolidine-1-carboxylate；9H-fluoren-9-ylmethyl 2-carbonochloridoylpyrrolidine-1-carboxylate
• CAS: 103321-52-4
• 化学式: C₂₀H₁₈ClNO₃
• 分子量: 355.821
• InChiKey: DKNLJWSDGPXALN-UHFFFAOYSA-N

物化性质

• 熔点：
  90-92 °C
• 沸点：
  503.6±43.0 °C(Predicted)
• 密度：
  1.328±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Fmoc-Pro(Cl) 在 samarium diiodide 作用下， 以 四氢呋喃 为溶剂， 以30%的产率得到1-(9-fluorenylmethoxycarbonyl)pyrrolidine
  参考文献：
  名称：

  Reactions of protected amino acid chlorides mediated by SmI2.

  摘要：

  Reactions of N-protected amino acid chlorides with carbonyl compounds in the presence of SmI2 were investigated. Decarbonylation followed by a cross coupling between amino moiety and aldehyde or ketone is observed. By the use of FMOC derivatives, N-protected amino alcohols were isolated in moderate yields.

  DOI：

  10.1016/s0040-4039(00)79575-x
• 作为产物：
  描述：

  Fmoc-DL-脯氨酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 Fmoc-Pro(Cl)
  参考文献：
  名称：

  [EN] DIMERS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS
  [FR] DIMÈRES DESTINÉS À ÊTRE UTILISÉS DANS LA SYNTHÈSE DE PEPTIDOMIMÉTIQUES

  摘要：

  本文描述了用于合成肽类类似物的二聚体。描述了二聚体作为合成氮杂肽和其他肽类类似物的合成物的合成物，以及从二聚体合成的氮杂肽和其他肽类类似物的用途。同时还描述了氮杂肽和其他肽类类似物的用途。

  公开号：

  WO2021226431A1

文献信息

• Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof
  申请人：Hardy Larry Wendell

  公开号：US20110319380A1

  公开（公告）日：2011-12-29

  Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了化合物及其合成方法。本文中提供的化合物可用于治疗、预防和/或管理各种疾病，如神经系统疾病、神经退行性疾病、神经精神疾病、认知、学习或记忆障碍、胃肠道疾病、下尿路障碍和癌症。本文提供的化合物在中枢神经系统或外周调节代谢性谷氨酸受体5(mGluR5)的活性。本文还提供了含有这些化合物的药物制剂及其使用方法。
• Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
  申请人：Hardy Larry Wendell

  公开号：US08772301B2

  公开（公告）日：2014-07-08

  Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了化合物及其合成方法。本文中所述的化合物可用于治疗、预防和/或管理各种疾病，如神经系统疾病、神经退行性疾病、神经精神疾病、认知、学习或记忆障碍、胃肠道疾病、下尿路障碍和癌症。本文中所述的化合物在中枢神经系统或外周调节代谢型谷氨酸受体5（mGluR5）的活性。本文还提供了含有这些化合物的药物制剂及其使用方法。
• COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20140349992A1

  公开（公告）日：2014-11-27

  Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了化合物及其合成方法。这些化合物可用于治疗、预防和/或管理各种疾病，如神经疾病、神经退行性疾病、神经精神疾病、认知、学习或记忆障碍、胃肠道疾病、下尿路障碍和癌症等。本文提供的化合物在中枢神经系统或外周调节代谢性谷氨酸受体5 (mGluR5) 的活性。本文还提供了含有这些化合物的药物制剂及其使用方法。
• BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS
  申请人：Bandiera Tiziano

  公开号：US20090136513A1

  公开（公告）日：2009-05-28

  A compound having formula (I): wherein: R, A, R 1 and R 2 , are as defined in the specification, and pharmaceutical formulas thereof, and methods of use thereof, as Kinase inhibitors.

  化合物的化学式为（I）：其中：R，A，R1和R2如规范中所定义，以及其药物配方和作为激酶抑制剂的使用方法。
• Proline analogs as ligands for cannabinoid receptors for the treatment of pain
  申请人：Purdue Pharma L.P.

  公开号：EP2583963A1

  公开（公告）日：2013-04-24

  The present invention relates to Proline Analog Compounds that are ligands for cannabinoid receptors, compositions comprising a Proline Analog Compound and a pharmaceutically-acceptable carrier, methods of making such Proline Analog Compounds, and methods for treating or preventing a Condition comprising administering an effective amount of a Proline Analog Compound to an animal in need thereof.

  本发明涉及作为大麻素受体配体的脯氨酸类似物化合物、包含脯氨酸类似物化合物和药学上可接受的载体的组合物、制造这种脯氨酸类似物化合物的方法，以及治疗或预防病症的方法，包括向需要的动物施用有效量的脯氨酸类似物化合物。